BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, Iodice V, Sagnelli C, Stanzione M, Capoluongo N, Pasquale G, Sagnelli E. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 2011;83:1909-16. [DOI: 10.1002/jmv.22199] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Sagnelli C, Montella L, Grimaldi P, Pisaturo M, Alessio L, De Pascalis S, Sagnelli E, Coppola N. COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature. Pathogens 2022;11:816. [DOI: 10.3390/pathogens11070816] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Pley C, Lourenço J, McNaughton AL, Matthews PC. Spacer Domain in Hepatitis B Virus Polymerase: Plugging a Hole or Performing a Role? J Virol 2022;96:e0005122. [PMID: 35412348 DOI: 10.1128/jvi.00051-22] [Reference Citation Analysis]
3 de Almeida NAA, de Paula VS. Occult Hepatitis B virus (HBV) infection and challenges for hepatitis elimination: A literature review. J Appl Microbiol 2021. [PMID: 34724308 DOI: 10.1111/jam.15351] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Yang J, König A, Park S, Jo E, Sung PS, Yoon SK, Zusinaite E, Kainov D, Shum D, Windisch MP. A new high-content screening assay of the entire hepatitis B virus life cycle identifies novel antivirals. JHEP Rep 2021;3:100296. [PMID: 34222850 DOI: 10.1016/j.jhepr.2021.100296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Pisaturo M, Onorato L, Russo A, Coppola N. Prevalence of occult HBV infection in Western countries. J Med Virol 2020. [PMID: 32275083 DOI: 10.1002/jmv.25867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
6 Pisaturo M, Onorato L, Russo A, Chiodini P, Coppola N. An estimation of the prevalence of occult HBV infection in Western Europe and in Northern America: A meta-analysis. J Viral Hepat 2020;27:415-27. [PMID: 31834645 DOI: 10.1111/jvh.13248] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
7 Pisaturo M, Macera M, Alessio L, Calò F, Coppola N. Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). Viruses 2019;11:E850. [PMID: 31540223 DOI: 10.3390/v11090850] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
8 Sagnelli C, Sagnelli E. Towards the worldwide eradication of hepatitis B virus infection: A combination of prophylactic and therapeutic factors. World J Clin Infect Dis 2019; 9(2): 11-22 [DOI: 10.5495/wjcid.v9.i2.11] [Cited by in CrossRef: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Msomi N, Ndlovu K, Giandhari J, Wilkinson E, Parboosing R, Zungu S, Mlisana K. High rate of occult hepatitis B virus infection in hemodialysis units of KwaZulu-Natal, South Africa. J Med Virol 2019;91:1797-803. [PMID: 31180137 DOI: 10.1002/jmv.25510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Tsai HM. Thrombotic Thrombocytopenic Purpura: Beyond Empiricism and Plasma Exchange. Am J Med 2019;132:1032-7. [PMID: 30928346 DOI: 10.1016/j.amjmed.2019.03.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Pisaturo M, Di Caprio G, Calò F, Portunato F, Martini S, Coppola N. Management of HBV reactivation in non-oncological patients. Expert Rev Anti Infect Ther 2018;16:611-24. [PMID: 30058401 DOI: 10.1080/14787210.2018.1505501] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
12 Lai A, Sagnelli C, Presti AL, Cella E, Angeletti S, Spoto S, Costantino S, Sagnelli E, Ciccozzi M. What is changed in HBV molecular epidemiology in Italy? J Med Virol. 2018;90:786-795. [PMID: 29315661 DOI: 10.1002/jmv.25027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
13 Marrone A, Capoluongo N, D'Amore C, Pisaturo M, Esposito M, Guastafierro S, Siniscalchi I, Macera M, Boemio A, Onorato L, Rinaldi L, Minichini C, Adinolfi LE, Sagnelli E, Mastrullo L, Coppola N. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy. J Viral Hepat. 2018;25:198-204. [PMID: 29029365 DOI: 10.1111/jvh.12802] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
14 Muraishi J, Shibata M, Honma Y, Hiura M, Abe S, Harada M. Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma. Intern Med 2017;56:1967-71. [PMID: 28768965 DOI: 10.2169/internalmedicine.56.8233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
15 Varaklioti A, Kouramba A, Ioannidou P, Katsarou O. Occult hepatitis B virus infection in Greek patients with congenital bleeding disorders. Infect Genet Evol 2017;54:397-401. [PMID: 28705716 DOI: 10.1016/j.meegid.2017.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
16 Coppola N, Onorato L, Sagnelli C, Sagnelli E, Angelillo IF. Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis. Medicine (Baltimore). 2016;95:e4311. [PMID: 27472708 DOI: 10.1097/md.0000000000004311] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
17 Sagnelli C, Ciccozzi M, Coppola N, Minichini C, Lo Presti A, Starace M, Alessio L, Macera M, Cella E, Gualdieri L, Caprio N, Pasquale G, Sagnelli E. Molecular diversity in irregular or refugee immigrant patients with HBV-genotype-E infection living in the metropolitan area of Naples. J Med Virol. 2017;89:1015-1024. [PMID: 27805272 DOI: 10.1002/jmv.24724] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
18 Makvandi M. Update on occult hepatitis B virus infection. World J Gastroenterol 2016; 22(39): 8720-8734 [PMID: 27818588 DOI: 10.3748/wjg.v22.i39.8720] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 86] [Article Influence: 15.5] [Reference Citation Analysis]
19 Hicks LK, Lien K, Chan KK. ASCO Provisional Clinical Opinion for Hepatitis B Virus Screening Before Cancer Therapy: Are These the Right Tests in the Right Patients? J Oncol Pract 2015;11:e490-4. [PMID: 26188049 DOI: 10.1200/JOP.2015.004945] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Sagnelli C, Macera M, Pisaturo M, Zampino R, Coppola M, Sagnelli E. Occult HBV infection in the oncohematological setting. Infection. 2016;44:575-582. [PMID: 27076347 DOI: 10.1007/s15010-016-0891-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
21 Powell EA, Boyce CL, Gededzha MP, Selabe SG, Mphahlele MJ, Blackard JT. Functional analysis of 'a' determinant mutations associated with occult HBV in HIV-positive South Africans. J Gen Virol 2016;97:1615-24. [PMID: 27031988 DOI: 10.1099/jgv.0.000469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
22 Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, Teshima T. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 2015; 7(21): 2344-2351 [PMID: 26413224 DOI: 10.4254/wjh.v7.i21.2344] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
23 Zampino R, Pisaturo MA, Cirillo G, Marrone A, Macera M, Rinaldi L, Stanzione M, Durante-Mangoni E, Gentile I, Sagnelli E, Signoriello G, Miraglia Del Giudice E, Adinolfi LE, Coppola N. Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Ann Hepatol. 2015;14:75-82. [PMID: 25536644 DOI: 10.1016/s1665-2681(19)30803-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
24 Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol. 2014;20:7635-7643. [PMID: 24976701 DOI: 10.3748/wjg.v20.i24.7635.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Ando T, Kojima K, Isoda H, Eguchi Y, Honda T, Ishigami M, Kimura S. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. Int J Hematol. 2015;102:379-382. [PMID: 25842192 DOI: 10.1007/s12185-015-1788-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
26 Kwak MS, Kim YJ. Occult hepatitis B virus infection. World J Hepatol 2014; 6(12): 860-869 [PMID: 25544873 DOI: 10.4254/wjh.v6.i12.860] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 6.6] [Reference Citation Analysis]
27 Powell EA, Gededzha MP, Rentz M, Rakgole NJ, Selabe SG, Seleise TA, Mphahlele MJ, Blackard JT. Mutations associated with occult hepatitis B in HIV-positive South Africans. J Med Virol 2015;87:388-400. [PMID: 25164924 DOI: 10.1002/jmv.24057] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
28 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immuno–suppressed patients. World J Hepatol. 2014;6:384-393. [PMID: 25018849 DOI: 10.4254/wjh.v6i6.384] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Sagnelli C, Ciccozzi M, Pisaturo M, Zehender G, Lo Presti A, Alessio L, Starace M, Lovero D, Sagnelli E, Coppola N. Molecular epidemiology of hepatitis B virus genotypes circulating in acute hepatitis B patients in the Campania region. J Med Virol. 2014;86:1683-1693. [PMID: 24980631 DOI: 10.1002/jmv.24005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
30 Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol 2014; 20(24): 7635-7643 [PMID: 24976701 DOI: 10.3748/wjg.v20.i24.7635] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 66] [Article Influence: 9.1] [Reference Citation Analysis]
31 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 2014; 6(6): 384-393 [PMID: 25018849 DOI: 10.4254/wjh.v6.i6.384] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
32 Seetharam A, Perrillo R, Gish R. Immunosuppression in Patients with Chronic Hepatitis B. Curr Hepatol Rep. 2014;13:235-244. [PMID: 25101233 DOI: 10.1007/s11901-014-0238-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
33 Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin Pharmacother. 2014;15:1337-1349. [PMID: 24773464 DOI: 10.1517/14656566.2014.913571] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
34 Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol 2014;14:31. [PMID: 24533834 DOI: 10.1186/1471-230X-14-31] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
35 Coppola N, Gentile I, Pasquale G, Buonomo AR, Capoluongo N, D’armiento M, Borgia G, Sagnelli E. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Annals of Hepatology 2014;13:20-6. [DOI: 10.1016/s1665-2681(19)30900-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
36 Coppola N, Marrone A, Pisaturo M, Starace M, Signoriello G, Gentile I, Adinolfi LE, Sagnelli E, Zampino R. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis. 2014;33:559-567. [PMID: 24081499 DOI: 10.1007/s10096-013-1985-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
37 Tramuto F, Maida CM, Colomba GM, Di Carlo P, Vitale F. Prevalence of occult hepatitis B virus infection in a cohort of HIV-positive patients resident in Sicily, Italy. Biomed Res Int. 2013;2013:859583. [PMID: 24063015 DOI: 10.1155/2013/859583] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
38 Coppola N, Loquercio G, Tonziello G, Azzaro R, Pisaturo M, Di Costanzo G, Starace M, Pasquale G, Cacciapuoti C, Petruzziello A. HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. J Clin Virol. 2013;58:315-317. [PMID: 23856167 DOI: 10.1016/j.jcv.2013.06.020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
39 Coppola N, Potenza N, Pisaturo M, Mosca N, Tonziello G, Signoriello G, Messina V, Sagnelli C, Russo A, Sagnelli E. Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS One. 2013;8:e65336. [PMID: 23843939 DOI: 10.1371/journal.pone.0065336] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
40 Fontenele AM, Filho NS, Ferreira AS. Occult hepatitis B in patients on hemodialysis: a review. Annals of Hepatology 2013;12:359-63. [DOI: 10.1016/s1665-2681(19)31335-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
41 Coppola N, Tonziello G, Colombatto P, Pisaturo M, Messina V, Moriconi F, Alessio L, Sagnelli C, Cavallone D, Brunetto M, Sagnelli E. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. J Infect. 2013;67:322-328. [PMID: 23796869 DOI: 10.1016/j.jinf.2013.06.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
42 Liu H, Zhao Z, Yang H, Liu F, Liu Q, Luo Q, Yuan Q, Chen L, Zeng A. The effects of nucleoside analogue prophylactic treatment on HBV activation in HBcAb+ patients undergoing immunosuppressive therapy. J Viral Hepat 2013;20:645-9. [DOI: 10.1111/jvh.12087] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
43 Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012;20:2999-3008. [PMID: 22933131 DOI: 10.1007/s00520-012-1576-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
44 Sagnelli E, Pisaturo M, Sagnelli C, Coppola N. Rituximab-based treatment, HCV replication, and hepatic flares. Clin Dev Immunol. 2012;2012:945950. [PMID: 22919406 DOI: 10.1155/2012/945950] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
45 Tonziello G, Pisaturo M, Sica A, Ferrara MG, Sagnelli C, Pasquale G, Sagnelli E, Guastafierro S, Coppola N. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection 2013;41:225-9. [DOI: 10.1007/s15010-012-0305-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
46 Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol 2013;35:39-52. [PMID: 22829332 DOI: 10.1007/s00281-012-0327-7] [Cited by in Crossref: 131] [Cited by in F6Publishing: 135] [Article Influence: 13.1] [Reference Citation Analysis]
47 Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy: Prevention of HBV reactivation. Hepatology Research 2012;42:627-36. [DOI: 10.1111/j.1872-034x.2012.00998.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
48 Chaulet P. Tuberculosis: a six-month cure. World Health Forum. 1989;10:116-122. [PMID: 2665766 DOI: 10.1016/j.critrevonc.2015.10.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.5] [Reference Citation Analysis]